Navigation Links
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Date:11/30/2009

(sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of the development and potential approval of Huxley's 3,4-Diaminopyridine product for the treatment of LEMS. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities, particularly the pending decision by the European Commission on the Marketing Authorization Application for such product, our success in the commercialization of such product, if approved; results and timing of current and planned preclinical studies and clinical trials related to such product; our ability to successfully manufacture the product; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-lo
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 ... research firm, announces the initiation of full ... biopharmaceutical company developing and marketing products for ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... examining the investment merits of BioAlliance Pharma, ...
(Date:6/18/2013)... , June 18, 2013  Techne Corporation ... that it has agreed to acquire 100% ownership ... Bionostics, Inc. (Bionostics).  Bionostics is a global leader ... solutions that verify the proper operation of ... in point of care blood glucose and blood ...
(Date:6/18/2013)... , June 18, 2013   Lexicon Pharmaceuticals, ... biopharmaceutical company focused on discovering breakthrough treatments for ... has joined the company as its vice ... Northcott brings extensive commercial experience to Lexicon, including ... variety of therapeutic areas. Mr. Northcott ...
(Date:6/18/2013)... 2013 Inflamax Research Inc., a ... and Phase I-IV clinical trials, announced today that ... Air Environmental Technologies (NAET), a specialty air conditioning ... and servicing of mobile Environmental Exposure Chambers (EECs) ... , Inflamax Research has proprietary ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and ... M.D, Chairman,and Chief Executive Officer, will present at ... at 3:50 pm Mountain Standard Time (5:50 pm,Eastern ... the Four Seasons,Resort in Scottsdale, Arizona. A live ...
... BRISBANE, Australia, Feb. 5 Xenome Limited today,announced ... Company,s Chief,Executive Officer. Dr. Nisbet will also join ... previously worked in senior management and executive,roles in ... Meditech Research Ltd, Millennium Pharmaceuticals Inc,and CSL Ltd. ...
... Blue Cross and Blue Shield of,Texas (BCBSTX) ... new integrated medical-dental program. The program is unique ... and dental data to,create a customized plan aimed ... to specifically help users optimize their overall health ...
Cached Biology Technology:Echo Therapeutics to Present at RedChip Small-Cap Investor Conference 2Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer 2Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program 2Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program 3
(Date:6/18/2013)... 2013 Joshua Obar, Ph.D., Department of Immunology and ... a 2013 ICAAC Young Investigator Award for his research ... responses to infection. , Obar earned his B.A. ... went on to complete his Ph.D. in Microbiology and ... his Ph.D. thesis research in Edward Usherwood,s laboratory at ...
(Date:6/18/2013)... modification of DNA and this modification can occur ... Until now, scientists believed that this epigenetic phenomenon ... a team of researchers from the University of ... Professor at the Faculty of Medicine, reveals that ... DNA methylation may play both a passive and ...
(Date:6/17/2013)... and other locations with central nervous system infections may ... discovered virus, according to a study to be published ... the American Society for Microbiology. Researchers have detected the ... patients with central nervous system infections of unknown cause, ... samples from pigs and poultry, suggesting animals may serve ...
Breaking Biology News(10 mins):The American Society for Microbiology honors Joshua Obar 2The secret of DNA methylation 2New virus discovered in patients with central nervous system infections 2New virus discovered in patients with central nervous system infections 3
... the flow of potassium in cells and revealed a potential ... form of a key such potassium channel was found to ... hub of people with the chronic mental illness and linked ... series of experiments suggest that selectively inhibiting this suspect form ...
... a leading cause of liver failure in the United States, ... of the University of Massachusetts Medical School (UMMS) has developed ... (HCV). The new antibody effectively neutralized the virus in ... pre-clinical animal model of the disease. Details of the ...
... announced details of a membership agreement with BioMed Central ... its researchers. Pfizer,s BioMed Central membership arrangement means ... any researcher employed or funded by Pfizer when they ... 190+ peer-reviewed open access journals. By funding open access ...
Cached Biology News:Flow of potassium into cells implicated in schizophrenia 2Flow of potassium into cells implicated in schizophrenia 3Novel antibody prevents infection by hepatitis C virus 2Novel antibody prevents infection by hepatitis C virus 3
...
... Mount is the standard water based mounting ... for the permanent preservation of peroxidase and ... easy to use and exhibits excellent optical ... aqueous mounting medium that permits the long-term ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
Request Info...
Biology Products: